Economic impact of pneumococcal protein-d conjugate vaccine (PHiD-CV) on the Malaysian National Immunization Programme
-
Sub-type Journal article Author Aljunid, Syed M.
Maimaiti, Namaitijiang
Ahmed, Zafar
Muhammad Nur, Amrizal
Md. Isa, Zaleha
Azmi, Soraya
Sulong, SaperiTitle Economic impact of pneumococcal protein-d conjugate vaccine (PHiD-CV) on the Malaysian National Immunization Programme Appearing in Value in Health Regional Issues Volume 3C Publication Date 2014-05-01 Place of Publication New York Publisher Elsevier Inc. Start page n/a End page n/a Language eng Abstract Objective
To assess the cost-effectiveness of introducing pneumococcal polysaccharide and nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in the National Immunization Programme of Malaysia. This study compared introducing PHiD-CV (10 valent vaccine) with current no vaccination, as well as against the alternative 13-valent pneumococcal conjugate vaccine (PCV13).
Methods
A lifetime Markov cohort model was adapted using national estimates of disease burden, outcomes of pneumococcal disease, and treatment costs of disease manifestations including pneumonia, acute otitis media, septicemia, and meningitis for a hypothetical birth cohort of 550,000 infants. Clinical information was obtained by review of medical records from four public hospitals in Malaysia from the year 2008 to 2009. Inpatient cost from the four study hospitals was obtained from a diagnostic-related group–based costing system. Outpatient cost was estimated using clinical pathways developed by an expert panel. The perspective assessed was that of the Ministry of Health, Malaysia.
Results
The estimated disease incidence was 1.2, 3.7, 70, and 6.9 per 100,000 population for meningitis, bacteremia, pneumonia, and acute otitis media, respectively. The Markov model predicted medical costs of Malaysian ringgit (RM) 4.86 billion (US $1.51 billion) in the absence of vaccination. Vaccination with PHiD-CV would be highly cost-effective against no vaccination at RM30,290 (US $7,407) per quality-adjusted life-year gained. On comparing PHiD-CV with PCV13, it was found that PHiD-CV dominates PCV13, with 179 quality-adjusted life-years gained while saving RM35 million (US $10.87 million).
Conclusions
It is cost-effective to incorporate pneumococcal vaccination in the National Immunization Programme of Malaysia. Our model suggests that PHiD-CV would be more cost saving than PCV13 from the perspective of the Ministry of Health of Malaysia.
Keyword Cost-effectiveness
Malaysia
Nontypeable haemophilus influenzae
Phid-cv
Pneumococcal conjugate vaccine
Pneumococcal protein-d conjugate vaccine
Streptococcus pneumoniae
13-valent pneumococcal conjugate vaccineCopyright Holder International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Copyright Year 2014 Copyright type Creative commons DOI 10.1016/j.vhri.2014.04.008 -
Citation counts Cited 0 times in Scopus Article
Search Google ScholarAccess Statistics: 514 Abstract Views - Detailed Statistics Created: Tue, 29 Sep 2015, 12:33:49 JST